

Zilretta™ (triamcinolone acetonide extended-release injectable suspension) J3490



When requesting Zilretta™ (triamcinolone acetonide extended-release injectable suspension), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved indication

Zilretta is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Approved Off-label Compendial use(s)

None

Coverage Guidelines

The individual meets all of the following criteria for approval:

- Has a diagnosis of osteoarthritis of knee
- Has not previously received Zilretta injection
- Has had an inadequate response, intolerance, or contraindication to at least 2 of the following therapies: acetaminophen [e.g., Tylenol®], non-steroidal anti-inflammatory drug(s) [e.g., Advil®, Motrin®], or tramadol (Ultram®)
- Has had an inadequate response to previous intra-articular corticosteroid injection

Approval duration: 1 dose

References

1. Zilretta prescribing information. Burlington, MA. Flexion Therapeutics, Inc., October 2017. Available at: http://www.zilrettalabel.com/PI.pdf?_ga=2.208921874.144372298.1510243580-582686676.1510243580 . Accessed November 09, 2017.
2. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee. *Arth Care Res.* 2003;64(4):465-474.
3. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical
4. Studies Including Therapeutic Trials (ESCISIT). *Ann Rheum Dis.* 2003;62(12):1145-1155.
5. Bruyere, O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis
6. in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of
7. Osteoporosis and Osteoarthritis (ESCEO). *Seminars in Arthritis and Rheumatism.* 2014;44:253-264.